PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Health

A precision T-cell therapy stalls treatment-resistant cancers in clinical trial

Marengo Therapeutics' Invikafusp alfa shows promise in treating TMB-H solid tumors resistant to standard immune checkpoint blockade.

6sources
6articles
4velocity
+31%since first seen
24d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

📍 How it ended

A precision T-cell therapy called invikafusp alfa demonstrated activity in TMB-H solid tumors during the Phase 1/2 START-001 trial. Results presented at ESMO 2026 showed the bispecific antibody shrunk eight tumor types in Phase 2.

The immunotherapy drug generated promising results for cancers mostly unresponsive to immune checkpoint blockade.

Epilogue added 20d ago, after coverage quieted.

The brief

A novel precision T-cell therapy called invikafusp alfa has demonstrated the ability to stall treatment-resistant cancers during a clinical trial. Developed by Marengo Therapeutics, this bispecific dual T-cell agonist was tested as part of the Phase 1/2 START-001 trial. The drug has shown tissue-agnostic single-agent activity specifically in solid tumors characterized by high tumor mutational burden (TMB-H). These tumors are noted for being mostly unresponsive to traditional immune checkpoint blockade. Results indicate that the therapy successfully shrunk tumors across eight different tumor types during its Phase 2 testing stage. Coverage of these developments has been widespread across scientific and mainstream outlets.

Nature provided a detailed look at the Phase 1/2 START-001 trial, while AOL.com specifically highlighted the drug's efficacy in TMB-H solid tumors. Medical Xpress focused on the therapy's ability to stall resistant cancers, and BioSpace emphasized the shrinking of eight tumor types. Additionally, Mass General Brigham reported that the immunotherapy drug generated promising clinical trial results, and the Toronto Star shared a personal account of a patient who viewed the early-stage Toronto treatment as a lifesaver after doctors had given him only two or three months to live. This development is significant because it targets a specific patient population—those with TMB-H solid tumors—who typically do not respond to current immune checkpoint blockade treatments. The nature of invikafusp alfa as a bispecific antibody allows it to act as a dual T-cell agonist, providing a different mechanism for immunotherapy. The transition from Phase 1 to Phase 2 testing suggests a progression in the drug's clinical validation.

By demonstrating tissue-agnostic activity, the treatment suggests it may work regardless of where the tumor is located in the body, provided the TMB-H marker is present. Future developments will center on the findings presented at ESMO 2026. Observers will be monitoring the continued results of the START-001 trial to see if the activity seen in the eight tumor types remains consistent. Coverage does not yet specify the long-term survival rates or the full range of side effects associated with invikafusp alfa. The focus remains on the drug's potential as a single-agent therapy for those who have failed other immunotherapy options. Further updates from Marengo Therapeutics regarding the expansion of these trials are expected following the ESMO 2026 presentations.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 21d ago.

Quick answers

What is the name of the drug used in the trial?

The drug is called invikafusp alfa, developed by Marengo Therapeutics.

Which specific types of tumors did the therapy target?

The therapy targeted TMB-H (high tumor mutational burden) solid tumors that were mostly unresponsive to immune checkpoint blockade.

Where were the Phase 2 results presented?

The results of the STARt-001 trial were presented at ESMO 2026.

Coverage (6)

Topics

Related trends

\n \n \n \n \n \n \n